Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

6 Months Ended

Dec. 31, 2020

	Bio-Techne Shareholders
											Accumulated
					Additional						Other
	Common Stock				Paid-in			Retained			Comprehensive			Noncontrolling
	Shares		Amount		Capital			Earnings			Income(Loss)			Interest			Total
Balances at June 30, 2020		38,453	$	385	$	420,536		$	1,057,470		$	(97,199	)	$	-		$	1,381,192
Cumulative effect adjustments due to adoption of new accounting standards									(276	)								(276	)
Net earnings									33,395									33,395
Other comprehensive income												14,057						14,057
Common stock issued for exercise of options		117		1		13,727												13,728
Common stock issued for restricted stock awards		25		0		(0	)		(4,890	)								(4,890	)
Cash dividends									(12,336	)								(12,336	)
Stock-based compensation expense						12,667												12,667
Common stock issued to employee stock purchase plan		6		0		1,463												1,463
Employee stock purchase plan expense						286												286
Balances at September 30, 2020		38,601	$	386	$	448,679		$	1,073,362		$	(83,142	)	$	-		$	1,439,285
Non-controlling interest in Eminence															8,985			8,985
Net earnings									46,274						(130	)		46,144
Other comprehensive income												18,904			83			18,987
Common stock issued for exercise of options		161		2		16,748			(2,482	)								14,268
Common stock issued for restricted stock awards		3		0		(0	)		0									0
Cash dividends									(12,392	)								(12,392	)
Stock-based compensation expense						15,471												15,471
Employee stock purchase plan expense						106												106
Balances at December 31, 2020		38,765	$	388	$	481,004		$	1,104,762		$	(64,238	)	$	8,938		$	1,530,854

											Accumulated
					Additional						Other
	Common Stock				Paid-in			Retained			Comprehensive
	Shares		Amount		Capital			Earnings			Income(Loss)			Total
Balances at June 30, 2019		37,934	$	379	$	316,797		$	931,934		$	(83,521	)	$	1,165,589
Cumulative effect adjustments due to adoption of new accounting standards and other									(879	)					(879	)
Net earnings									14,398						14,398
Other comprehensive loss												(8,106	)		(8,106	)
Common stock issued for exercise of options		94		1		7,854									7,855
Common stock issued for restricted stock awards		50		0		(0	)		(1,926	)					(1,926	)
Cash dividends									(12,169	)					(12,169	)
Stock-based compensation expense						8,267									8,267
Common stock issued to employee stock purchase plan		6		0		1,096									1,096
Employee stock purchase plan expense						99									99
Balances at September 30, 2019		38,084	$	381	$	334,112		$	931,358		$	(91,627	)	$	1,174,224
Net earnings									119,622						119,622
Other comprehensive loss												13,275			13,275
Common stock issued for exercise of options		195		2		18,293									18,295
Common stock issued for restricted stock awards		4		0		(0	)								0
Cash dividends									(12,197	)					(12,197	)
Stock-based compensation expense						10,017									10,017
Common stock issued to employee stock purchase plan															0
Employee stock purchase plan expense						112									112
Balances at December 31, 2019		38,283	$	383	$	362,534		$	1,038,783		$	(78,352	)	$	1,323,348

	Unrealized Gains (Losses) on Derivative Instruments			Foreign Currency Translation Adjustments			Total
Balance as of June 30, 2020 attributable to Bio-Techne	$	(13,253	)	$	(83,946	)	$	(97,199	)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne		(47)			28,759			28,712
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne⁽¹⁾		4,249			-			4,249
Balance as of December 31, 2020 attributable to Bio-Techne⁽³⁾	$	(9,051	)	$	(55,187	)	$	(64,238	)

	Unrealized Gains (Losses) on Derivative Instruments			Foreign Currency Translation Adjustments			Total
Balance as of June 30, 2019 attributable to Bio-Techne	$	(9,537	)	$	(73,983	)	$	(83,521	)
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne		275			4,264			4,539
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne⁽²⁾		629			-			629
Balance as of December 31, 2019 attributable to Bio-Techne⁽³⁾	$	(8,633	)	$	(69,719	)	$	(78,352	)